The financial impact of physician practice patterns: An analysis of as-needed filgrastim versus prophylactic pegfilgrastim in patients with prostate cancer receiving docetaxel.

被引：0
|
作者：
Barrett, Christine
Park, Seon Jo
Gaertner, Kelly
Mao, Shifeng
机构：
[1] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA
[2] Allegheny Hlth Network, Inst Canc, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.6506
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6506
引用
收藏
页数：1
相关论文
共 5 条
  • [1] Clinical Impact of Primary Prophylactic Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy
    Jeon, Ye Won
    Lim, Seung Taek
    Gwak, HongKi
    Park, Seon Young
    Suh, Young Jin
    JOURNAL OF BREAST CANCER, 2020, 23 (05) : 521 - 532
  • [2] Analysis of ANC recovery from a Phase III study of lipegfilgrastim versus pegfilgrastim in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
    Bondarenko, I.
    Bias, P.
    Elsaesser, R.
    Buchner, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S434 - S435
  • [3] Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis
    von Minckwitz, G.
    Schwenkglenks, M.
    Skacel, T.
    Lyman, G. H.
    Pousa, A. Lopez
    Bacon, P.
    Easton, V.
    Aapro, M. S.
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (04) : 608 - 617
  • [4] Risk of febrile neutropenia as a function of age and disease stage in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management - results from the NeuCuP analysis
    Aapro, M.
    Schwenkglenks, M.
    Lyman, G.
    Lopez-Pousa, A.
    Bacon, F.
    Lawrinson, S.
    Von Minckwitz, G.
    EJC SUPPLEMENTS, 2008, 6 (07): : 195 - 196
  • [5] Reduced incidence of febrile neutropenia and related complications in elderly breast cancer patients receiving chemotherapy with pegfilgrastim primary prophylaxis versus current practice neutropenia management - results from an integrated analysis
    Aapro, M.
    Schwenkglenks, M.
    Lyman, G.
    Lopez Pousa, A.
    Easton, V
    Skacel, T.
    Bacon, P.
    Von Minckwitz, G.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S72 - S72
1